Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HUTCHMED (China) Limited

http://www.hmplglobal.com

Latest From HUTCHMED (China) Limited

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

Commercial Deals

Takeda Pays Big For De-Risked HutchMed CRC Drug

The Japanese pharma agreed to pay $400m up front plus up to $730m in milestones for a colorectal cancer drug already on the market in China and nearing regulatory filings in the US, EU and Japan.

Deals Business Strategies

10 Years On, Chinese Biopharma Firms Making US Inroads: A Snapshot

From 2013 to November 2022, Chinese pharma companies as a single sponsor started a total of 35 international Phase III clinical studies for innovative drugs in the US, indicating a continuing push by the biopharma sector in the country to leverage increasing innovation to access this huge and lucrative market. Led by BeiGene, 20 firms have placed their bets on such studies and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.

China Clinical Trials

10 Years On, Chinese Biopharma Firms Making Inroads In US Clinical Trials

Led by BeiGene, 20 firms have placed their bets on Phase III clinical studies for innovative drugs in the US and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.

Clinical Trials Diversity & Inclusion
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Chi-Med
    • Hutchison Whampoa
    • Sinopharm Pharmaceuticals Company Limited
    • Hutchison MediPharma Limited
    • Hutchison China MediTech Limited
UsernamePublicRestriction

Register